EXACT Sciences (EXAS) Receives Daily Media Impact Score of 0.13

Headlines about EXACT Sciences (NASDAQ:EXAS) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. EXACT Sciences earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 45.8282399108614 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment’s rankings:

EXAS has been the subject of a number of research reports. Bank of America set a $56.00 price target on shares of EXACT Sciences and gave the stock a “buy” rating in a report on Thursday, October 19th. BidaskClub upgraded shares of EXACT Sciences from a “buy” rating to a “strong-buy” rating in a report on Friday, August 25th. Canaccord Genuity restated a “buy” rating and issued a $45.00 price target on shares of EXACT Sciences in a report on Thursday, September 7th. Leerink Swann restated an “outperform” rating and issued a $67.00 price target (up from $63.00) on shares of EXACT Sciences in a report on Monday, November 13th. Finally, Robert W. Baird cut shares of EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 price target for the company. in a report on Monday, November 13th. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $50.58.

Shares of EXACT Sciences (EXAS) traded up $0.23 during midday trading on Wednesday, hitting $53.73. 2,119,090 shares of the stock were exchanged, compared to its average volume of 2,471,000. EXACT Sciences has a 52-week low of $13.05 and a 52-week high of $63.60. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.07. The firm had revenue of $72.60 million during the quarter, compared to analysts’ expectations of $65.03 million. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The business’s revenue was up 158.4% on a year-over-year basis. During the same period last year, the company earned ($0.36) earnings per share. research analysts anticipate that EXACT Sciences will post -1.12 EPS for the current fiscal year.

In related news, insider Kevin T. Conroy sold 134,057 shares of the business’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total transaction of $7,976,391.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin T. Conroy sold 137,805 shares of the business’s stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $59.14, for a total transaction of $8,149,787.70. Following the transaction, the chief executive officer now owns 967,867 shares in the company, valued at $57,239,654.38. The disclosure for this sale can be found here. Insiders have sold 473,547 shares of company stock valued at $26,440,940 over the last quarter. Corporate insiders own 4.00% of the company’s stock.

WARNING: “EXACT Sciences (EXAS) Receives Daily Media Impact Score of 0.13” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://ledgergazette.com/2017/12/06/exact-sciences-exas-receives-daily-media-impact-score-of-0-13.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply